Asset Details
Do you wish to reserve the book?
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Do you wish to request the book?
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007
Overview
The prognosis in metastatic renal-cell cancer, especially of the dominant clear-cell type, is dismal. This trial compared sorafenib, an orally active inhibitor of the proliferation of cancer cells and tumor angiogenesis, with placebo in patients with metastatic clear-cell renal cancer. The results with sorafenib were modest but encouraging enough to test the drug as an initial adjuvant treatment.
This trial compared sorafenib, an orally active inhibitor of the proliferation of cancer cells and tumor angiogenesis, with placebo in patients with metastatic clear-cell renal cancer. The results with sorafenib were modest but encouraging enough to test the drug as an initial adjuvant treatment.
The 5-year survival rate for patients with metastatic renal-cell carcinoma is less than 10%.
1
High-dose interleukin-2 therapy rarely induces a durable complete response, and interferon alfa provides only a modest survival advantage. Until recently, there have been no other treatments for patients with renal-cell carcinoma who are ineligible for, or unable to tolerate, these cytokines.
2
–
6
Sorafenib, an orally active multikinase inhibitor with effects on tumor-cell proliferation and tumor angiogenesis, was initially identified as a Raf kinase inhibitor.
7
It also inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3; platelet-derived growth factor receptor β (PDGFRβ); FMS-like tyrosine kinase . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Benzenesulfonates - adverse effects
/ Benzenesulfonates - therapeutic use
/ Biological and medical sciences
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - mortality
/ Female
/ Humans
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - mortality
/ Kidneys
/ Male
/ Nephrology. Urinary tract diseases
/ Niacinamide - analogs & derivatives
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
